Hutchmed Announces NDA Acceptance in China for Savolitinib MET Inhibitor Hutchmed, a leading biopharma company focused on cancer therapies, has announced that its regulatory submission for Savolitinib has been accepted as a New Drug Application (NDA) in China. This development comes on the heels of a positive Phase II registration study in Chinese patients and…